Diseases | Novartis

Press Release
Apr 17, 2024

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Press Release
Jan 05, 2024

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
Press Release
Dec 08, 2023

Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
Press Release
Dec 11, 2023

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
Press Release
Sep 14, 2023

Novartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
Story
May 09, 2023

Q&A: Addressing unmet needs for people living with PNH, a rare and chronic blood disorder
Landing Page

Diseases
Story
Jun 21, 2021

Discover how inflammation could fan the flames of cancer
Story
Sep 14, 2021

Doing the right thing is good business
Story
Mar 22, 2017

Striving to vanquish leukemia
Story
Mar 02, 2021

Take a visual tour of medicines that target RNA
Story
Sep 28, 2017

Novartis and UC Berkeley take on “undruggable” proteins in new collaboration